Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis

Introduction Statin-associated immune-mediated necrotizing myositis (IMNM) is a rare but distinct idiopathic inflammatory myopathy (IIM) that requires early recognition and intervention to prevent irreversible muscle damage. It typically characterized by active statin use, elevated creatinine kinase (CK) levels, proximal weakness, at times, positive 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) antibody. Treatment includes immediate discontinuation of the may include corticosteroids, intravenous immunoglobulin (IVIG), and/or immunosuppressive therapy. Inclusion body (IBM), another IIM, also presents with CK levels insidious onset distal upper lower extremity weakness refractory treatment. Case Description 64-year-old female patient presented HMGCR antibody in setting use pathology suggestive both statin-associated IMNM IBM. She responded subcutaneous methotrexate slow prednisone taper over several months, however, will require close monitoring for symptoms associated either disease. Conclusion In conclusion, we report case demonstrating This highlights importance understanding clinical pathological features